Target intelligence / Profile preview

DNA guanine O⁶ position (O⁶-G) (O⁶-G)

Target
O⁶-G
Molecular classification
Other, Nucleic acid
01

Overview

The DNA guanine O⁶ position is a critical nucleophilic site within the DNA double helix that serves as the primary target for alkylating chemotherapeutic agents such as temozolomide and nitrosoureas [PubChem; NIH NCI]. Alkylation at this position, particularly methylation, creates O⁶-methylguanine lesions that are highly cytotoxic to cancer cells [PubMed: 15150602]. These lesions are lethal because they frequently mispair with thymine during DNA replication, which triggers the cellular mismatch repair (MMR) system to initiate a futile cycle of repair that results in double-strand breaks and apoptosis [Nature Reviews Cancer, 2004]. The effectiveness of drugs targeting this site is largely determined by the presence of the repair enzyme O⁶-methylguanine-DNA methyltransferase (MGMT), which can remove the alkyl group and restore the DNA, leading to drug resistance [UniProt: P16455]. Consequently, the methylation status of the MGMT promoter is a vital clinical biomarker for predicting response to therapy in patients with glioblastoma [NEJM, 2005]. However, because these drugs also alkylate DNA in healthy tissues, they are associated with significant toxicities, including severe myelosuppression and an increased risk of developing secondary leukemias [FDA: Temozolomide Label].

Other names
O6-alkylguanineO6-methylguanine siteGuanine O6 position
02

Mechanism of action

Alkylating agents transfer alkyl groups to the O6 position of guanine, creating O6-alkylguanine [PubChem]. This lesion mispairs with thymine during DNA replication [PubMed: 15150602]. The mismatch is recognized by the mismatch repair (MMR) system, which leads to double-strand breaks and apoptosis [Nature Reviews Cancer, 2004].

03

Biological functions

ApoptosisCell cycleCell deathOther
04

Disease associations

Cancer
05

Safety considerations

Myelosuppression (anemia, leukopenia, thrombocytopenia) [FDA Label]Secondary malignancies such as acute myeloid leukemia (AML) [PubMed: 18505920]Hepatotoxicity [FDA Label]Teratogenicity [FDA Label]Nausea and vomiting [MedlinePlus]
06

Interacting drugs

Temozolomide

5 more in the full profile.

07

Biomarkers

MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation status [NEJM, 2005]MGMT protein expression [PubMed: 15150602]Mismatch repair (MMR) proficiency [PubMed: 11433307]

Beyond the preview

Go deeper on DNA guanine O⁶ position (O⁶-G) (O⁶-G).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA guanine O⁶ position (O⁶-G) (O⁶-G).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call